Polysaccharide-Based Drug Carriers-A Patent Analysis
Ilić-Stojanović S., Damiri F., Musuc AM., Berrada M.
Narrative Review, published in Gels (2024) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Gels (2024)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 39727561
- PMCID
- PMC11675155
- DOI
- 10.3390/gels10120801
- Citations
- 4
Abstract (original English)
Polysaccharide-based carriers as biomaterials for drug delivery have been inspiring scientists for years due to their exceptional characteristics, such as nontoxicity, biocompatibility, and degradability, as they are able to protect pharmaceutically active molecules and provide their controlled/modified release. This review focuses on selected drug delivery systems based on natural polymers, namely fucoidan, pullulan, dextran, and pectin, with the aim of highlighting published patent documents. The information contained in patents is very important because it is usually not published in any other document and is much less discussed as the state of the art in the scientific literature. The Espacenet-European Patent Office database and the International Patent Classification were used for the research to highlight the specific search procedure. The presented analysis of the innovative state of the art includes an overview from the first patent applications to the latest granted patents in this field.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.